Charles Schwab
QNCX icon

Charles Schwab’s Quince Therapeutics QNCX Stock Holding History

Charles Schwab’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-55
Closed -$8.26K – 3565
2024
Q2 		$8.26K Hold
55
– – ﹤0.01% 3619
2024
Q1 		$11.7K Hold
55
– – ﹤0.01% 3457
2023
Q4 		$11.6K Hold
55
– – ﹤0.01% 3517
2023
Q3 		$12.3K Hold
55
– – ﹤0.01% 3551
2023
Q2 		$16.6K Hold
55
– – ﹤0.01% 3578
2023
Q1 		$17.2K Hold
55
– – ﹤0.01% 3517
2022
Q4 		$7.02K Hold
55
– – ﹤0.01% 3541
2022
Q3 		$15K Sell
55
-433
-89% -$165K ﹤0.01% 3494
2022
Q2 		$217K Sell
488
-95
-16% -$67.2K ﹤0.01% 3232
2022
Q1 		$723K Sell
583
-47
-7% -$64K ﹤0.01% 2979
2021
Q4 		$1.59M Buy
630
+9
+1% +$54.9K ﹤0.01% 2774
2021
Q3 		$11.4M Buy
621
+92
+17% +$1.46M ﹤0.01% 1931
2021
Q2 		$5.61M Buy
529
+50
+10% +$419K ﹤0.01% 2294
2021
Q1 		$3.45M Buy
479
+18
+4% +$130K ﹤0.01% 2468
2020
Q4 		$2.56M Buy
461
+1
+0.2% +$8.86K ﹤0.01% 2528
2020
Q3 		$4.6M Buy
460
+176
+62% +$1.6M ﹤0.01% 2099
2020
Q2 		$2.63M Buy
284
+66
+30% +$605K ﹤0.01% 2321
2020
Q1 		$1.99M Buy
218
+3
+1% +$29.6K ﹤0.01% 2279
2019
Q4 		$2.41M Buy
215
+92
+75% +$555K ﹤0.01% 2363
2019
Q3 		$612K Sell
123
-1
-0.8% -$6.15K ﹤0.01% 2722
2019
Q2 		$1.05M Buy
+124
New +$741K ﹤0.01% 2560

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab's QNCX Position: Q3 2024 in Review

Charles Schwab sold out of Quince Therapeutics (QNCX) in Q3 2024, closing a stake of 55 shares — an estimated $8.26K sold.

Charles Schwab first reported a position in QNCX in Q2 2019 and held it in 21 quarters. The position peaked at $11.4M in Q3 2021. 32 funds tracked by Wall St. Rank hold QNCX as of Q3 2024.

  • Charles Schwab reported no remaining Quince Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 55 Quince Therapeutics shares in Q3 2024, an estimated $8.26K.
  • Charles Schwab first reported a position in Quince Therapeutics in Q2 2019 and held it in 21 quarters.
  • Charles Schwab's Quince Therapeutics position peaked at $11.4M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.